$287.24
8.112.91%
At Close: -
$287.24
00.00%
After Hours: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Madrigal Pharmaceuticals
MDGLNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock, Analyst Ratings, Price Targets, Forecasts
Madrigal Pharmaceuticals Inc has a consensus price target of $334.87 based on the ratings of 17 analysts. The high is $410 issued by UBS on March 15, 2024. The low is $150 issued by B of A Securities on April 22, 2024. The 3 most-recent analyst ratings were released by JMP Securities, B. Riley Securities, and HC Wainwright & Co. on July 16, 2024, May 10, 2024, and May 8, 2024, respectively. With an average price target of $325 between JMP Securities, B. Riley Securities, and HC Wainwright & Co., there's an implied 13.15% upside for Madrigal Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
B. Riley Securities
HC Wainwright & Co.
Citigroup
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Madrigal Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/16/2024 | Buy Now | 34.03% | JMP Securities | Jonathan Wolleben | $381 → $385 | Maintains | Market Outperform | Get Alert |
| 06/28/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal | — | Initiates | → Neutral | Get Alert |
| 06/11/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Initiates | → Outperform | Get Alert |
| 05/10/2024 | Buy Now | -30.37% | B. Riley Securities | Mayank Mamtani | $270 → $200 | Maintains | Neutral | Get Alert |
| 05/08/2024 | Buy Now | 35.77% | HC Wainwright & Co. | Ed Arce | $425 → $390 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 32.99% | Citigroup | David Lebovitz | $389 → $382 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 32.64% | JMP Securities | Jonathan Wolleben | $397 → $381 | Maintains | Market Outperform | Get Alert |
| 04/22/2024 | Buy Now | -47.78% | B of A Securities | Alexandria Hammond | → $150 | Initiates | → Underperform | Get Alert |
| 03/20/2024 | Buy Now | 41% | Evercore ISI Group | Liisa Bayko | $325 → $405 | Maintains | Outperform | Get Alert |
| 03/15/2024 | Buy Now | 42.74% | UBS | Eliana Merle | $337 → $410 | Maintains | Buy | Get Alert |
| 03/15/2024 | Buy Now | 35.77% | TD Cowen | Ritu Baral | $349 → $390 | Maintains | Outperform | Get Alert |
| 03/15/2024 | Buy Now | -6% | B. Riley Securities | Mayank Mamtani | $155 → $270 | Upgrade | Sell → Neutral | Get Alert |
| 03/15/2024 | Buy Now | 35.43% | Citigroup | David Lebovitz | $382 → $389 | Maintains | Buy | Get Alert |
| 03/15/2024 | Buy Now | 38.21% | JMP Securities | Jonathan Wolleben | — | Maintains | Outperform | Get Alert |
| 03/15/2024 | Buy Now | 30.55% | Oppenheimer | Jay Olson | $320 → $375 | Maintains | Outperform | Get Alert |
| 03/15/2024 | Buy Now | 31.25% | Canaccord Genuity | Edward Nash | $338 → $377 | Maintains | Buy | Get Alert |
| 03/15/2024 | Buy Now | 47.96% | HC Wainwright & Co. | Ed Arce | $405 → $425 | Maintains | Buy | Get Alert |
| 03/14/2024 | Buy Now | 16.98% | Piper Sandler | Yasmeen Rahimi | → $336 | Reiterates | Overweight → Overweight | Get Alert |
| 03/12/2024 | Buy Now | 41% | HC Wainwright & Co. | Ed Arce | $275 → $405 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 17.67% | Canaccord Genuity | Edward Nash | $336 → $338 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 32.99% | Citigroup | David Lebowitz | → $382 | Initiates | → Buy | Get Alert |
| 03/01/2024 | Buy Now | 11.41% | Oppenheimer | Jay Olson | $300 → $320 | Maintains | Outperform | Get Alert |
| 02/27/2024 | Buy Now | -46.04% | B. Riley Securities | Mayank Mamtani | $204 → $155 | Downgrade | Neutral → Sell | Get Alert |
| 02/26/2024 | Buy Now | -46.04% | B. Riley Securities | Mayank Mamtani | → $155 | Downgrade | Neutral → Sell | Get Alert |
| 02/23/2024 | Buy Now | 20.8% | JMP Securities | Jonathan Wolleben | → $347 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/16/2024 | Buy Now | 20.8% | JMP Securities | Jonathan Wolleben | → $347 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/24/2024 | Buy Now | 16.98% | Piper Sandler | Yasmeen Rahimi | $305 → $336 | Maintains | Overweight | Get Alert |
| 11/14/2023 | Buy Now | 33.34% | JMP Securities | Jonathan Wolleben | → $383 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/13/2023 | Buy Now | -4.26% | HC Wainwright & Co. | Ed Arce | $225 → $275 | Maintains | Buy | Get Alert |
| 09/19/2023 | Buy Now | 13.15% | Evercore ISI Group | Liisa Bayko | $325 → $325 | Maintains | Outperform | Get Alert |
| 09/14/2023 | Buy Now | -21.67% | HC Wainwright & Co. | Ed Arce | → $225 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | -21.67% | HC Wainwright & Co. | Ed Arce | → $225 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2023 | Buy Now | -22.02% | B. Riley Securities | Mayank Mamtani | → $224 | Reiterates | Neutral → Neutral | Get Alert |
| 09/05/2023 | Buy Now | -22.02% | B. Riley Securities | Mayank Mamtani | → $224 | Reiterates | Neutral → Neutral | Get Alert |
| 08/09/2023 | Buy Now | -0.78% | Oppenheimer | Jay Olson | $350 → $285 | Maintains | Outperform | Get Alert |
| 07/18/2023 | Buy Now | 16.98% | Canaccord Genuity | Edward Nash | → $336 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 21.85% | Oppenheimer | Jay Olson | $300 → $350 | Maintains | Outperform | Get Alert |
| 05/10/2023 | Buy Now | 16.98% | Canaccord Genuity | Edward Nash | → $336 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 16.98% | Canaccord Genuity | Edward Nash | $296 → $336 | Maintains | Buy | Get Alert |
| 02/27/2023 | Buy Now | 4.44% | Oppenheimer | Jay Olson | $250 → $300 | Maintains | Outperform | Get Alert |
| 01/05/2023 | Buy Now | 35.77% | JMP Securities | Jonathan Wolleben | $312 → $390 | Maintains | Market Outperform | Get Alert |
| 12/21/2022 | Buy Now | 17.32% | UBS | Eliana Merle | $161 → $337 | Maintains | Buy | Get Alert |
| 12/20/2022 | Buy Now | 13.15% | Evercore ISI Group | Liisa Bayko | $175 → $325 | Maintains | Outperform | Get Alert |
| 12/20/2022 | Buy Now | -21.67% | HC Wainwright & Co. | Ed Arce | $170 → $225 | Maintains | Buy | Get Alert |
| 12/20/2022 | Buy Now | -12.96% | Oppenheimer | Jay Olson | $170 → $250 | Maintains | Outperform | Get Alert |
| 12/20/2022 | Buy Now | 30.55% | Goldman Sachs | Andrea Tan | $178 → $375 | Maintains | Buy | Get Alert |
| 12/20/2022 | Buy Now | 8.62% | JMP Securities | Jonathan Wolleben | $182 → $312 | Maintains | Market Outperform | Get Alert |
| 12/20/2022 | Buy Now | 9.66% | SVB Leerink | Mike Kratky | $145 → $315 | Maintains | Outperform | Get Alert |
| 07/08/2022 | Buy Now | -73.89% | B. Riley Securities | Mayank Mamtani | $131 → $75 | Downgrade | Buy → Neutral | Get Alert |
| 05/10/2022 | Buy Now | -39.08% | Evercore ISI Group | Liisa Bayko | → $175 | Maintains | Outperform | Get Alert |
| 05/10/2022 | Buy Now | -40.82% | JMP Securities | Jonathan Wolleben | $200 → $170 | Maintains | Market Outperform | Get Alert |
| 05/10/2022 | Buy Now | -40.82% | Oppenheimer | Jay Olson | $180 → $170 | Maintains | Outperform | Get Alert |
| 01/31/2022 | Buy Now | -30.72% | Evercore ISI Group | Liisa Bayko | $199 → $199 | Maintains | Outperform | Get Alert |
| 12/20/2021 | Buy Now | -30.72% | Evercore ISI Group | Liisa Bayko | $199 → $199 | Maintains | Outperform | Get Alert |
| 11/17/2021 | Buy Now | -30.72% | Evercore ISI Group | Liisa Bayko | → $199 | Maintains | Outperform | Get Alert |
| 10/07/2021 | Buy Now | -47.43% | Jefferies | Akash Tewari | — | Initiates | → Buy | Get Alert |
| 08/11/2021 | Buy Now | -40.82% | HC Wainwright & Co. | Ed Arce | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Madrigal Pharmaceuticals (MDGL) stock?
The latest price target for Madrigal Pharmaceuticals (NASDAQ:MDGL) was reported by JMP Securities on July 16, 2024. The analyst firm set a price target for $385.00 expecting MDGL to rise to within 12 months (a possible 34.03% upside). 35 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Madrigal Pharmaceuticals (MDGL)?
The latest analyst rating for Madrigal Pharmaceuticals (NASDAQ:MDGL) was provided by JMP Securities, and Madrigal Pharmaceuticals maintained their market outperform rating.
When was the last upgrade for Madrigal Pharmaceuticals (MDGL)?
The last upgrade for Madrigal Pharmaceuticals Inc happened on March 15, 2024 when B. Riley Securities raised their price target to $270. B. Riley Securities previously had a sell for Madrigal Pharmaceuticals Inc.
When was the last downgrade for Madrigal Pharmaceuticals (MDGL)?
The last downgrade for Madrigal Pharmaceuticals Inc happened on February 27, 2024 when B. Riley Securities changed their price target from $204 to $155 for Madrigal Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Madrigal Pharmaceuticals (MDGL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Madrigal Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Madrigal Pharmaceuticals was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
Is the Analyst Rating Madrigal Pharmaceuticals (MDGL) correct?
While ratings are subjective and will change, the latest Madrigal Pharmaceuticals (MDGL) rating was a maintained with a price target of $381.00 to $385.00. The current price Madrigal Pharmaceuticals (MDGL) is trading at is $287.24, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.